Evolus Reports Q3 2026 Financial Results
Evolus, Inc. announced its third-quarter 2026 financial results, highlighting 13% revenue growth and a fourth consecutive quarter of positive adjusted EBITDA.
Stocks · News reference
FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Raises Price Target on Evolus to $15
BTIG maintained its 'Buy' rating on Evolus, Inc. and increased its price target from $13 to $15.
8-K filing — Evolus, Inc. (EOLS)
Filed: 2026-11-04 AccNo: 0001628280-26-070150 Size: 408 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Evolus Management to Participate in Upcoming Investor Conferences
Evolus, Inc. announced that its management team will participate in investor conferences in New York and London in November 2026.
Evolus, Inc. Schedules Third Quarter 2026 Financial Results Announcement
Evolus, Inc. has announced that it will release its financial results for the third quarter of 2026 on November 4, 2026.
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.